Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Solasia Pharma KK ( (JP:4597) ) has issued an announcement.
Solasia Pharma K.K. has revised its earnings forecast for the fiscal year ending December 31, 2024, due to a new agreement with Changchun GeneScience Pharmaceutical Co., Ltd. for the exclusive sales rights of episil® in China. The company expects an increase in revenue by 140 million yen from previous forecasts, largely attributed to a lump-sum contract payment and sales royalties from GenSci. However, despite the increased revenue, the company forecasts an operating loss of 1,050 million yen, which is an improvement from the previous estimate due to adjustments in R&D and SG&A expenses.
More about Solasia Pharma KK
Solasia Pharma K.K. operates in the pharmaceutical industry, focusing on the development and commercialization of innovative oncology medicines. The company has a significant market presence in Asia, particularly in China, where it collaborates with local pharmaceutical partners to enhance its product distribution.
YTD Price Performance: 3.68%
Average Trading Volume: 196
Technical Sentiment Consensus Rating: Strong Buy
Current Market Cap: €48.39M
See more insights into 4597 stock on TipRanks’ Stock Analysis page.